Renin-angiotensin-aldosterone system inhibitors (RAASi) are a group of drugs that include angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB). Numerous randomized clinical trials proved that both reduce morbidity and mortality in patients with hypertension, heart failure, and chronic kidney disease; therefore, professional societies recommend using ACEi and ARB as the cornerstone of hypertension therapy [1–6]. The latest hypertension guidelines favor using combination drugs, preferably in a single pill (SPC) [3,5,6].
